- Investing.com
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Metrics to compare | 8QQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship8QQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.5x | −0.5x | |
PEG Ratio | 0.00 | 0.08 | 0.00 | |
Price/Book | 0.0x | 1.1x | 2.6x | |
Price / LTM Sales | 0.0x | 1.9x | 3.3x | |
Upside (Analyst Target) | 0.0% | 51.6% | 45.1% | |
Fair Value Upside | Unlock | 38.0% | 7.4% | Unlock |